Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

INMB stock hub

INmune Bio Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

INMBis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

38M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

INMB

In the news

Latest news · INMB

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-168.8

P25 -105.6P50 -46.5P75 -3.1

ROIC-65.4

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All INMB market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

177

Groups with data

Currency

USD

Showing 177 of 177 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001711754
Company name	INmune Bio Inc.
Country	United States
Country code	US
Cusip	45782T105
Employees	21
Employees Change	-1%
Employees Change Percent	-4.55
Enterprise value	$18.2M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2019-02-04
Isin	US45782T1051
Last refreshed	2026-05-10
Market cap	$38M
Market cap category	Nano-Cap
Price	$1.43
Price currency	USD
Sector	Healthcare
Sic	2836
Symbol	INMB
Website	https://www.inmunebio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-109.43%
FCF yield	-53.14%
P/B ratio	1.94x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-41.6M
Net Income Growth Quarters	3%
Net Income Growth Years	0%
Profit Per Employee	$-2M
ROA	-52.61
Roa5y	-35.88
ROCE	-131.1
ROE	-168.8
Roe5y	-87.2
ROIC	-65.43

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-79.99%
Cagr3y	-43.8%
Cagr5y	-33.13%
EPS Growth Quarters	3
EPS Growth Years	1
Revenue Growth	257.14x
Revenue Growth Years	1x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$25.8M
Cash	$21.4M
Current Assets	$22.8M
Current Liabilities	$5.4M
Debt	$1.5M
Debt Equity	$0.08
Equity	$19.6M
Liabilities	$6.2M
Long Term Assets	$3M
Long Term Liabilities	$806,000
Net Cash	$19.8M
Net Cash By Market Cap	$52.21
Net Cash Growth	4.52%
Net Debt Equity	$-1.01
Tangible Book Value	$19.6M
Tangible Book Value Per Share	$0.74
WACC	9.63

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.24
Net Working Capital	$-3.2M
Quick ratio	4.11
Working Capital	$17.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-22.4%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-79.97%
200-day SMA	1.74
3Y total return	-82.26%
50-day SMA	1.32
50-day SMA vs 200-day SMA	50under200
5Y total return	-86.62%
All Time High	30.37
All Time High Change	-95.29%
All Time High Date	2021-09-07
All Time Low	1.09
All Time Low Change	31.19%
All Time Low Date	2026-03-31
ATR	0.09
Beta	1.05
Beta1y	1.64
Beta2y	0.97
Ch YTD	-8.33
High	1.51
High52	11.64
High52 Date	2025-06-27
High52ch	-87.71%
Low	1.41
Low52	1.09
Low52 Date	2026-03-31
Low52ch	31.19%
Ma50ch	8.33%
Price vs 200-day SMA	-17.63%
RSI	52.66
RSI Monthly	35.24
RSI Weekly	40.89
Sharpe ratio	-1.04x
Sortino ratio	-1.23
Total Return	-22.4%
Tr YTD	-8.33
Tr1m	12.6%
Tr1w	-5.3%
Tr3m	-5.3%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	5
Analyst Ratings	Buy
Earnings EPS Estimate	$-0.21
Operating Income	$-26.8M
Price target	$5.4
Price Target Change	$278

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	22,162,600%
Float Percent	83.36%
Shares Insiders	11.17%
Shares Institutions	19.31%
Shares Out	26,585,258
Shares Qo Q	-0.08%
Shares Yo Y	22.4%
Short Float	15.2%
Short Ratio	7.85
Short Shares	12.67

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-29.5M
Average Volume	238,128.95x
Bv Per Share	0.74
CAPEX	$-1M
Ch1m	12.6
Ch1w	-5.3
Ch1y	-79.97
Ch3m	-5.3
Ch3y	-82.26
Ch5y	-86.62
Ch6m	-12.27
Change	0%
Change From Open	1.42
Close	1.43
Days Gap	-1.4
Depreciation Amortization	136,000
Dollar Volume	343,365.9
Earnings Date	2026-05-07
Earnings Time	amc
EBIT	$-26.8M
EPS	$-1.61
F Score	2
FCF	$-20.2M
FCF EV Yield	-111.2x
FCF Per Share	$-0.76
Financing CF	22,338,000
Fiscal Year End	December
Founded	2,015
Investing CF	-1,042,000
Ipr	-82.13
Iprfo	-83.06
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-30
Ma150	1.56
Ma150ch	-8.22%
Ma20	1.41
Ma20ch	1.35%
Net CF	2,021,000
Next Earnings Date	2026-08-06
Open	1.41
Optionable	Yes
Position In Range	21.05
Post Close	1.43
Postmarket Change Percent	1.4
Postmarket Price	$1.45
Ppne	2,313,000
Price Date	2026-05-08
Ptbv Ratio	1.94
Relative Volume	1.01x
Share Based Comp	9,331,000
Tr6m	-12.27%
Us State	Florida
Volume	240,116

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does INMB pay a dividend?

Capital-return profile for this ticker.

Performance

INMB stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns INMB?

Insider, institutional, and short-interest positioning.

Institutional ownership

+19.3%

Float: +83.4% of shares outstanding

Insider ownership

+11.2%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

INMB momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

52.7

Neutral momentum band

Price vs 200-day MA

-17.6%

50/200-day relationship not available

Beta (5Y)

1.05

Moves roughly with the market

Sharpe ratio

-1.04

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About INMB

Hub-level FAQ points readers to the deeper analysis pages.

What is the current INMB stock rating?

INmune Bio Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full INMB analysis?

The full report lives at /stocks/INMB/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for INMB?

The latest report frames INMB around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the INMB page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.